Login Register Cart 0
Generic placeholder image

当代肿瘤药物靶点

Editor-in-Chief

ISSN (Print): 1568-0096
ISSN (Online): 1873-5576

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in English
Review Article

通过TRKA信号调节肿瘤发生性和肿瘤转移

卷 24, 期 3, 2024

发表于: 20 September, 2023

页: [271 - 287] 页: 17

弟呕挨: 10.2174/1568009623666230904150957

价格: $65

conference banner
摘要

原肌球蛋白受体激酶(TRK) A, TRKA，是神经生长因子(NGF)的特异性结合受体，在人类癌症的发生和发展中起着至关重要的作用。TRKA过表达已被证明是一个强大的致癌驱动因素，并已在许多肿瘤中得到证实。TRKA受体激酶结构域以ngf依赖的方式过度激活，伴随着下游信号通路的激活，如RAS-MAPK、PI3K-AKT、JAK2-STAT3通路、PLC γ通路和Hippo通路，这些信号通路参与肿瘤细胞增殖、侵袭、上皮-间质转化(EMT)、神经周侵袭(PNI)、耐药和癌痛。此外，NTRK1与其他基因融合产生的嵌合癌基因也是肿瘤发生和癌症发展的直接原因。新开发的TRK抑制剂可以改善TRKA或NTRK1融合基因过表达的癌症患者的症状和肿瘤消退。随着耐药的出现，下一代TRK抑制剂在TRK激酶结构域突变的情况下仍能保持较强的临床疗效，这些抑制剂正在临床试验中。本文综述了TRKA的特点及研究进展，重点介绍了TRKA信号通路在不同肿瘤中的调控作用。此外，我们还总结了TRKA及TRK抑制剂的临床意义。本文综述可能为研究TRKA在不同肿瘤中的作用机制提供新的参考，也为深入了解TRKA作为生物标志物和治疗靶点在人类癌症中的作用提供新的视角。

关键词: TRKA, TRKA过表达，TRKA融合，TRKA抑制剂，靶向治疗，致瘤性。

« Previous Next »
图形摘要

[1]
Snider, W.D. Functions of the neurotrophins during nervous system development: What the knockouts are teaching us. Cell, 1994, 77(5), 627-638.
[http://dx.doi.org/10.1016/0092-8674(94)90048-5] [PMID: 8205613]
[2]
Kaplan, D.R.; Martin-Zanca, D.; Parada, L.F. Tyrosine phosphorylation and tyrosine kinase activity of the trk proto-oncogene product induced by NGF. Nature, 1991, 350(6314), 158-160.
[http://dx.doi.org/10.1038/350158a0] [PMID: 1706478]
[3]
Soppet, D.; Escandon, E.; Maragos, J.; Middlemas, D.S.; Raid, S.W.; Blair, J.; Burton, L.E.; Stanton, B.R.; Kaplan, D.R.; Hunter, T.; Nikolics, K.; Parade, L.F. The neurotrophic factors brain-derived neurotrophic factor and neurotrophin-3 are ligands for the trkB tyrosine kinase receptor. Cell, 1991, 65(5), 895-903.
[http://dx.doi.org/10.1016/0092-8674(91)90396-G] [PMID: 1645620]
[4]
Davies, A.M.; Horton, A.; Burton, L.E.; Schmelzer, C.; Vandlen, R.; Rosenthal, A. Neurotrophin-4/5 is a mammalian-specific survival factor for distinct populations of sensory neurons. J. Neurosci., 1993, 13(11), 4961-4967.
[http://dx.doi.org/10.1523/JNEUROSCI.13-11-04961.1993] [PMID: 8229208]
[5]
Lamballe, F.; Klein, R.; Barbacid, M. trkC, a new member of the trk family of tyrosine protein kinases, is a receptor for neurotrophin-3. Cell, 1991, 66(5), 967-979.
[http://dx.doi.org/10.1016/0092-8674(91)90442-2] [PMID: 1653651]
[6]
Ip, N.Y.; Stitt, T.N.; Tapley, P.; Klein, R.; Glass, D.J.; Fandl, J.; Greene, L.A.; Barbacid, M.; Yancopoulos, G.D. Similarities and differences in the way neurotrophins interact with the Trk receptors in neuronal and nonneuronal cells. Neuron, 1993, 10(2), 137-149.
[http://dx.doi.org/10.1016/0896-6273(93)90306-C] [PMID: 7679912]
[7]
Yuan, Y.; Ye, H.Q.; Ren, Q.C. Upregulation of the BDNF/TrKB pathway promotes epithelial-mesenchymal transition, as well as the migration and invasion of cervical cancer. Int. J. Oncol., 2017, 52(2), 461-472.
[http://dx.doi.org/10.3892/ijo.2017.4230] [PMID: 29345295]
[8]
Khotskaya, Y.B.; Holla, V.R.; Farago, A.F.; Mills Shaw, K.R.; Meric-Bernstam, F.; Hong, D.S. Targeting TRK family proteins in cancer. Pharmacol. Ther., 2017, 173, 58-66.
[http://dx.doi.org/10.1016/j.pharmthera.2017.02.006] [PMID: 28174090]
[9]
Kim, M.S.; Jeong, J.; Seo, J.; Kim, H.S.; Kim, S.J.; Jin, W. Dysregulated JAK2 expression by TrkC promotes metastasis potential, and EMT program of metastatic breast cancer. Sci. Rep., 2016, 6(1), 33899.
[http://dx.doi.org/10.1038/srep33899] [PMID: 27654855]
[10]
Lin, C.; Ren, Z.; Yang, X.; Yang, R.; Chen, Y.; Liu, Z.; Dai, Z.; Zhang, Y.; He, Y.; Zhang, C.; Wang, X.; Cao, W.; Ji, T. Nerve growth factor (NGF)-TrkA axis in head and neck squamous cell carcinoma triggers EMT and confers resistance to the EGFR inhibitor erlotinib. Cancer Lett., 2020, 472, 81-96.
[http://dx.doi.org/10.1016/j.canlet.2019.12.015] [PMID: 31838083]
[11]
Huson, S.M.; Staab, T.; Pereira, M.; Ward, H.; Paredes, R.; Evans, D.G. Infantile fibrosarcoma with Tpm3-Ntrk1 fusion in a boy with bloom syndrome. Fam. Cancer, 2020.
[http://dx.doi.org/10.1007/s10689-020-00221-1] [PMID: 33219493]
[12]
Wiesner, T.; He, J.; Yelensky, R.; Esteve-Puig, R.; Botton, T.; Yeh, I.; Lipson, D.; Otto, G.; Brennan, K.; Murali, R.; Garrido, M.; Miller, V.A.; Ross, J.S.; Berger, M.F.; Sparatta, A.; Palmedo, G.; Cerroni, L.; Busam, K.J.; Kutzner, H.; Cronin, M.T.; Stephens, P.J.; Bastian, B.C. Kinase fusions are frequent in Spitz tumours and spitzoid melanomas. Nat. Commun., 2014, 5(1), 3116.
[http://dx.doi.org/10.1038/ncomms4116] [PMID: 24445538]
[13]
Gatalica, Z.; Xiu, J.; Swensen, J.; Vranic, S. Molecular characterization of cancers with NTRK gene fusions. Mod. Pathol., 2019, 32(1), 147-153.
[http://dx.doi.org/10.1038/s41379-018-0118-3] [PMID: 30171197]
[14]
Brodeur, G.M.; Nakagawara, A.; Yamashiro, D.J.; Ikegaki, N.; Liu, X.G.; Azar, C.G.; Lee, C.P.; Evans, A.E. Expression of TrkA, TrkB and TrkC in human neuroblastomas. J. Neurooncol., 1997, 31(1/2), 49-56.
[http://dx.doi.org/10.1023/A:1005729329526] [PMID: 9049830]
[15]
Kamiya, A.; Inokuchi, M.; Otsuki, S.; Sugita, H.; Kato, K.; Uetake, H.; Sugihara, K.; Takagi, Y.; Kojima, K. Prognostic value of tropomyosin-related kinases A, B, and C in gastric cancer. Clin. Transl. Oncol., 2016, 18(6), 599-607.
[http://dx.doi.org/10.1007/s12094-015-1407-7] [PMID: 26459250]
[16]
Lawn, S.; Krishna, N.; Pisklakova, A.; Qu, X.; Fenstermacher, D.A.; Fournier, M.; Vrionis, F.D.; Tran, N.; Chan, J.A.; Kenchappa, R.S.; Forsyth, P.A. Neurotrophin signaling via TrkB and TrkC receptors promotes the growth of brain tumor-initiating cells. J. Biol. Chem., 2015, 290(6), 3814-3824.
[http://dx.doi.org/10.1074/jbc.M114.599373] [PMID: 25538243]
[17]
Ohta, T.; Watanabe, T.; Katayama, Y.; Kurihara, J.; Yoshino, A.; Nishimoto, H.; Kishimoto, H. TrkA expression is associated with an elevated level of apoptosis in classic medulloblastomas. Neuropathology, 2006, 26(3), 170-177.
[http://dx.doi.org/10.1111/j.1440-1789.2006.00678.x] [PMID: 16771171]
[18]
Tajima, Y.; Molina, R.P., Jr; Rorke, L.B.; Kaplan, D.R.; Radeke, M.; Feinstein, S.C.; Lee, V.M.Y.; Trojanowski, J.Q. Neurotrophins and neuronal versus glial differentiation in medulloblastomas and other pediatric brain tumors. Acta Neuropathol., 1998, 95(4), 325-332.
[http://dx.doi.org/10.1007/s004010050806] [PMID: 9560008]
[19]
Regua, A.T.; Aguayo, N.R.; Jalboush, S.A.; Doheny, D.L.; Manore, S.G.; Zhu, D.; Wong, G.L.; Arrigo, A.; Wagner, C.J.; Yu, Y.; Thomas, A.; Chan, M.D.; Ruiz, J.; Jin, G.; Strowd, R.; Sun, P.; Lin, J.; Lo, H.W. TrkA interacts with and phosphorylates STAT3 to enhance gene transcription and promote breast cancer stem cells in triple-negative and HER2-enriched breast cancers. Cancers, 2021, 13(10), 2340.
[http://dx.doi.org/10.3390/cancers13102340] [PMID: 34066153]
[20]
Sakamoto, Y.; Kitajima, Y.; Edakuni, G.; Hamamoto, T.; Miyazaki, K. Combined evaluation of NGF and p75NGFR expression is a biomarker for predicting prognosis in human invasive ductal breast carcinoma. Oncol. Rep., 2001, 8(5), 973-980.
[http://dx.doi.org/10.3892/or.8.5.973] [PMID: 11496301]
[21]
Rasi, G.; Serafino, A.; Bellis, L.; Lonardo, M.T.; Andreola, F.; Zonfrillo, M.; Vennarecci, G.; Pierimarchi, P.; Sinibaldi Vallebona, P.; Ettorre, G.M.; Santoro, E.; Puoti, C. Nerve growth factor involvement in liver cirrhosis and hepatocellular carcinoma. World J. Gastroenterol., 2007, 13(37), 4986-4995.
[http://dx.doi.org/10.3748/wjg.v13.i37.4986] [PMID: 17854142]
[22]
Flørenes, V.A.; Mælandsmo, G.M.; Holm, R.; Reich, R.; Lazarovici, P.; Davidson, B. Expression of activated TrkA protein in melanocytic tumors: Relationship to cell proliferation and clinical outcome. Am. J. Clin. Pathol., 2004, 122(3), 412-420.
[http://dx.doi.org/10.1309/CHFHEYAT44WWP7J3] [PMID: 15362372]
[23]
Miknyoczki, S.J.; Lang, D.; Huang, L.; Klein-Szanto, A.J.P.; Dionne, C.A.; Ruggeri, B.A. Neurotrophins and Trk receptors in human pancreatic ductal adenocarcinoma: Expression patterns and effects on in vitro invasive behavior. Int. J. Cancer, 1999, 81(3), 417-427.
[http://dx.doi.org/10.1002/(SICI)1097-0215(19990505)81:3<417:AID-IJC16>3.0.CO;2-6] [PMID: 10209957]
[24]
Dang, C.; Zhang, Y.; Ma, Q.; Shimahara, Y. Expression of nerve growth factor receptors is correlated with progression and prognosis of human pancreatic cancer. J. Gastroenterol. Hepatol., 2006, 21(5), 850-858.
[http://dx.doi.org/10.1111/j.1440-1746.2006.04074.x] [PMID: 16704535]
[25]
Ricci, A.; Greco, S.; Mariotta, S.; Felici, L.; Bronzetti, E.; Cavazzana, A.; Cardillo, G.; Amenta, F.; Bisetti, A.; Barbolini, G. Neurotrophins and neurotrophin receptors in human lung cancer. Am. J. Respir. Cell Mol. Biol., 2001, 25(4), 439-446.
[http://dx.doi.org/10.1165/ajrcmb.25.4.4470] [PMID: 11694449]
[26]
Gao, F.; Griffin, N.; Faulkner, S.; Rowe, C.W.; Williams, L.; Roselli, S.; Thorne, R.F.; Ferdoushi, A.; Jobling, P.; Walker, M.M.; Hondermarck, H. The neurotrophic tyrosine kinase receptor TrkA and its ligand NGF are increased in squamous cell carcinomas of the lung. Sci. Rep., 2018, 8(1), 8135.
[http://dx.doi.org/10.1038/s41598-018-26408-2] [PMID: 29802376]
[27]
McGregor, L.M.; McCune, B.K.; Graff, J.R.; McDowell, P.R.; Romans, K.E.; Yancopoulos, G.D.; Ball, D.W.; Baylin, S.B.; Nelkin, B.D. Roles of trk family neurotrophin receptors in medullary thyroid carcinoma development and progression. Proc. Natl. Acad. Sci. USA, 1999, 96(8), 4540-4545.
[http://dx.doi.org/10.1073/pnas.96.8.4540] [PMID: 10200298]
[28]
Mauri, G.; Valtorta, E.; Cerea, G.; Amatu, A.; Schirru, M.; Marrapese, G.; Fiorillo, V.; Recchimuzzo, P.; Cavenago, I.S.; Bonazzina, E.F.; Motta, V.; Lauricella, C.; Veronese, S.; Tosi, F.; Maiolani, M.; Rospo, G.; Truini, M.; Bonoldi, E.; Christiansen, J.; Potts, S.J.; Siena, S.; Sartore-Bianchi, A. TRKA expression and NTRK1 gene copy number across solid tumours. J. Clin. Pathol., 2018, 71(10), 926-931.
[http://dx.doi.org/10.1136/jclinpath-2018-205124] [PMID: 29802225]
[29]
Kim, M.S.; Kim, G.M.; Choi, Y.J.; Kim, H.J.; Kim, Y.J.; Jin, W. c-Src activation through a TrkA and c-Src interaction is essential for cell proliferation and hematological malignancies. Biochem. Biophys. Res. Commun., 2013, 441(2), 431-437.
[http://dx.doi.org/10.1016/j.bbrc.2013.10.082] [PMID: 24369899]
[30]
Mei, L.C.; Zhuo, L.S.; Xu, H.C.; Huang, W.; Hao, G.F.; Yang, G.F. Conformational adjustment overcomes multiple drug-resistance mutants of tropomyosin receptor kinase. Eur. J. Med. Chem., 2022, 237, 114406.
[http://dx.doi.org/10.1016/j.ejmech.2022.114406] [PMID: 35486994]
[31]
Passiglia, F.; Caparica, R.; Giovannetti, E.; Giallombardo, M.; Listi, A.; Diana, P.; Cirrincione, G.; Caglevic, C.; Raez, L.E.; Russo, A.; Rolfo, C. The potential of neurotrophic tyrosine kinase (NTRK) inhibitors for treating lung cancer. Expert Opin. Investig. Drugs, 2016, 25(4), 385-392.
[http://dx.doi.org/10.1517/13543784.2016.1152261] [PMID: 26881293]
[32]
Vaishnavi, A.; Capelletti, M.; Le, A.T.; Kako, S.; Butaney, M.; Ercan, D.; Mahale, S.; Davies, K.D.; Aisner, D.L.; Pilling, A.B.; Berge, E.M.; Kim, J.; Sasaki, H.; Park, S.; Kryukov, G.; Garraway, L.A.; Hammerman, P.S.; Haas, J.; Andrews, S.W.; Lipson, D.; Stephens, P.J.; Miller, V.A.; Varella-Garcia, M.; Jänne, P.A.; Doebele, R.C. Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nat. Med., 2013, 19(11), 1469-1472.
[http://dx.doi.org/10.1038/nm.3352] [PMID: 24162815]
[33]
Narayanan, R.; Yepuru, M.; Coss, C.C.; Wu, Z.; Bauler, M.N.; Barrett, C.M.; Mohler, M.L.; Wang, Y.; Kim, J.; Snyder, L.M.; He, Y.; Levy, N.; Miller, D.D.; Dalton, J.T. Discovery and preclinical characterization of novel small molecule TRK and ROS1 tyrosine kinase inhibitors for the treatment of cancer and inflammation. PLoS One, 2013, 8(12), e83380.
[http://dx.doi.org/10.1371/journal.pone.0083380] [PMID: 24386191]
[34]
Di Donato, M.; Cernera, G.; Migliaccio, A.; Castoria, G. Nerve growth factor induces proliferation and aggressiveness in prostate cancer cells. Cancers, 2019, 11(6), 784.
[http://dx.doi.org/10.3390/cancers11060784] [PMID: 31174415]
[35]
Stratton, M.R. Exploring the genomes of cancer cells: Progress and promise. Science, 2011, 331(6024), 1553-1558.
[http://dx.doi.org/10.1126/science.1204040] [PMID: 21436442]
[36]
Valastyan, S.; Weinberg, R.A. Tumor metastasis: molecular insights and evolving paradigms. Cell, 2011, 147(2), 275-292.
[http://dx.doi.org/10.1016/j.cell.2011.09.024] [PMID: 22000009]
[37]
Lemmon, M.A.; Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell, 2010, 141(7), 1117-1134.
[http://dx.doi.org/10.1016/j.cell.2010.06.011] [PMID: 20602996]
[38]
Singh, R.; Karri, D.; Shen, H.; Shao, J.; Dasgupta, S.; Huang, S.; Edwards, D.P.; Ittmann, M.M.; O’Malley, B.W.; Yi, P. TRAF4-mediated ubiquitination of NGF receptor TrkA regulates prostate cancer metastasis. J. Clin. Invest., 2018, 128(7), 3129-3143.
[http://dx.doi.org/10.1172/JCI96060] [PMID: 29715200]
[39]
Lagadec, C.; Meignan, S.; Adriaenssens, E.; Foveau, B.; Vanhecke, E.; Romon, R.; Toillon, R.A.; Oxombre, B.; Hondermarck, H.; Le Bourhis, X. TrkA overexpression enhances growth and metastasis of breast cancer cells. Oncogene, 2009, 28(18), 1960-1970.
[http://dx.doi.org/10.1038/onc.2009.61] [PMID: 19330021]
[40]
Bollig-Fischer, A.; Michelhaugh, S.K.; Wijesinghe, P.; Dyson, G.; Kruger, A.; Palanisamy, N.; Choi, L.; Alosh, B.; Ali-Fehmi, R.; Mittal, S. Cytogenomic profiling of breast cancer brain metastases reveals potential for repurposing targeted therapeutics. Oncotarget, 2015, 6(16), 14614-14624.
[http://dx.doi.org/10.18632/oncotarget.3786] [PMID: 25970776]
[41]
Kyker-Snowman, K.; Hughes, R.M.; Yankaskas, C.L.; Cravero, K.; Karthikeyan, S.; Button, B.; Waters, I.; Rosen, D.M.; Dennison, L.; Hunter, N.; Donaldson, J.; Christenson, E.S.; Konstantopoulos, K.; Hurley, P.J.; Croessmann, S.; Park, B.H. TrkA overexpression in non-tumorigenic human breast cell lines confers oncogenic and metastatic properties. Breast Cancer Res. Treat., 2020, 179(3), 631-642.
[http://dx.doi.org/10.1007/s10549-019-05506-3] [PMID: 31823098]
[42]
Trouvilliez, S.; Cicero, J.; Lévêque, R.; Aubert, L.; Corbet, C.; Van Outryve, A.; Streule, K.; Angrand, P.O.; Völkel, P.; Magnez, R.; Brysbaert, G.; Mysiorek, C.; Gosselet, F.; Bourette, R.; Adriaenssens, E.; Thuru, X.; Lagadec, C.; de Ruyck, J.; Orian-Rousseau, V.; Le Bourhis, X.; Toillon, R.A. Direct interaction of TrkA/CD44v3 is essential for NGF-promoted aggressiveness of breast cancer cells. J. Exp. Clin. Cancer Res., 2022, 41(1), 110.
[http://dx.doi.org/10.1186/s13046-022-02314-4] [PMID: 35346305]
[43]
Garrido, M.P.; Vallejos, C.; Girardi, S.; Gabler, F.; Selman, A.; López, F.; Vega, M.; Romero, C. NGF/TRKA promotes ADAM17-dependent cleavage of P75 in ovarian cells: Elucidating a pro-tumoral mechanism. Int. J. Mol. Sci., 2022, 23(4), 2124.
[http://dx.doi.org/10.3390/ijms23042124] [PMID: 35216240]
[44]
Vizza, D.; Perri, A.; Toteda, G.; Lupinacci, S.; Leone, F.; Gigliotti, P.; Lofaro, D.; La Russa, A.; Bonofiglio, R. Nerve growth factor exposure promotes tubular epithelial–mesenchymal transition via TGF- β 1 signaling activation. Growth Factors, 2015, 33(3), 169-180.
[http://dx.doi.org/10.3109/08977194.2015.1054989] [PMID: 26066770]
[45]
Tripathi, V.; Sixt, K.M.; Gao, S.; Xu, X.; Huang, J.; Weigert, R.; Zhou, M.; Zhang, Y.E. Direct regulation of alternative splicing by SMAD3 through PCBP1 is essential to the tumor-promoting role of TGF-β. Mol. Cell, 2016, 64(3), 549-564.
[http://dx.doi.org/10.1016/j.molcel.2016.09.013] [PMID: 27746021]
[46]
Yang, X.; Shen, H.; Buckley, B.; Chen, Y.; Yang, N.; Mussell, A.L.; Chernov, M.; Kobzik, L.; Frangou, C.; Han, S.X.; Zhang, J. NTRK1 is a positive regulator of YAP oncogenic function. Oncogene, 2019, 38(15), 2778-2787.
[http://dx.doi.org/10.1038/s41388-018-0609-1] [PMID: 30542115]
[47]
Nakamura, K.; Tan, F.; Li, Z.; Thiele, C.J. NGF activation of TrkA induces vascular endothelial growth factor expression via induction of hypoxia-inducible factor-1α. Mol. Cell. Neurosci., 2011, 46(2), 498-506.
[http://dx.doi.org/10.1016/j.mcn.2010.12.002] [PMID: 21145972]
[48]
Liebig, C.; Ayala, G.; Wilks, J.A.; Berger, D.H.; Albo, D. Perineural invasion in cancer. Cancer, 2009, 115(15), 3379-3391.
[http://dx.doi.org/10.1002/cncr.24396] [PMID: 19484787]
[49]
Renz, B.W. Takahashi, R.; Tanaka, T.; Macchini, M.; Hayakawa, Y.; Dantes, Z.; Maurer, H.C.; Chen, X.; Jiang, Z.; Westphalen, C.B.; Ilmer, M.; Valenti, G.; Mohanta, S.K.; Habenicht, A.J.R.; Middelhoff, M.; Chu, T.; Nagar, K.; Tailor, Y.; Casadei, R.; Di Marco, M.; Kleespies, A.; Friedman, R.A.; Remotti, H.; Reichert, M.; Worthley, D.L.; Neumann, J.; Werner, J.; Iuga, A.C.; Olive, K.P.; Wang, T.C. β2 adrenergic-neurotrophin feedforward loop promotes pancreatic cancer. Cancer Cell, 2018, 33(1), 75-90.e7.
[http://dx.doi.org/10.1016/j.ccell.2017.11.007] [PMID: 29249692]
[50]
Li, J.; Ma, J.; Han, L.; Xu, Q.; Lei, J.; Duan, W.; Li, W.; Wang, F.; Wu, E.; Ma, Q.; Huo, X. Hyperglycemic tumor microenvironment induces perineural invasion in pancreatic cancer. Cancer Biol. Ther., 2015, 16(6), 912-921.
[http://dx.doi.org/10.1080/15384047.2015.1040952] [PMID: 25946624]
[51]
Hayakawa, Y.; Sakitani, K.; Konishi, M.; Asfaha, S.; Niikura, R.; Tomita, H.; Renz, B.W.; Tailor, Y.; Macchini, M.; Middelhoff, M.; Jiang, Z.; Tanaka, T.; Dubeykovskaya, Z.A.; Kim, W.; Chen, X.; Urbanska, A.M.; Nagar, K.; Westphalen, C.B.; Quante, M.; Lin, C.S.; Gershon, M.D.; Hara, A.; Zhao, C.M.; Chen, D.; Worthley, D.L.; Koike, K.; Wang, T.C. Nerve growth factor promotes gastric tumorigenesis through aberrant cholinergic signaling. Cancer Cell, 2017, 31(1), 21-34.
[http://dx.doi.org/10.1016/j.ccell.2016.11.005] [PMID: 27989802]
[52]
Pundavela, J.; Demont, Y.; Jobling, P.; Lincz, L.F.; Roselli, S.; Thorne, R.F.; Bond, D.; Bradshaw, R.A.; Walker, M.M.; Hondermarck, H. ProNGF correlates with Gleason score and is a potential driver of nerve infiltration in prostate cancer. Am. J. Pathol., 2014, 184(12), 3156-3162.
[http://dx.doi.org/10.1016/j.ajpath.2014.08.009] [PMID: 25285721]
[53]
Liebl, F.; Demir, I.E.; Mayer, K.; Schuster, T.; D’Haese, J.G.; Becker, K.; Langer, R.; Bergmann, F.; Wang, K.; Rosenberg, R.; Novotny, A.R.; Feith, M.; Reim, D.; Friess, H.; Ceyhan, G.O. The impact of neural invasion severity in gastrointestinal malignancies: A clinicopathological study. Ann. Surg., 2014, 260(5), 900-908.
[http://dx.doi.org/10.1097/SLA.0000000000000968] [PMID: 25379860]
[54]
Yang, T.; Li, J.; Zhuo, Z.; Zeng, H.; Tan, T.; Miao, L.; Zheng, M.; Yang, J.; Pan, J.; Hu, C.; Zou, Y.; He, J.; Xia, H. TTF1 suppresses neuroblastoma growth and induces neuroblastoma differentiation by targeting TrkA and the miR-204/TrkB axis. iScience, 2022, 25(7), 104655.
[http://dx.doi.org/10.1016/j.isci.2022.104655] [PMID: 35811845]
[55]
Liu, D.; Xue, D.; Lu, W.; Yang, Z.; Li, L.; Xia, B.; Wei, J.; Chen, X.; Yang, Y.; Wang, X.; Lin, G. BDE-47 induced PC-12 cell differentiation via TrkA downstream pathways and caused the loss of hippocampal neurons in BALB/c mice. J. Hazard. Mater., 2022, 422, 126850.
[http://dx.doi.org/10.1016/j.jhazmat.2021.126850] [PMID: 34419847]
[56]
Marsland, M.; Dowdell, A.; Jiang, C.C.; Wilmott, J.S.; Scolyer, R.A.; Zhang, X.D.; Hondermarck, H.; Faulkner, S. Expression of NGF/proNGF and their receptors TrkA, p75NTR and sortilin in melanoma. Int. J. Mol. Sci., 2022, 23(8), 4260.
[http://dx.doi.org/10.3390/ijms23084260] [PMID: 35457078]
[57]
Zhu, Z.W.; Friess, H.; Wang, L.; Di Mola, F.F.; Zimmermann, A.; Büchler, M.W. Down-regulation of nerve growth factor in poorly differentiated and advanced human esophageal cancer. Anticancer Res., 2000, 20(1A), 125-132.
[PMID: 10769644]
[58]
Griffin, N.; Gao, F.; Jobling, P.; Oldmeadow, C.; Wills, V.; Walker, M.M.; Faulkner, S.; Hondermarck, H. The neurotrophic tyrosine kinase receptor 1 (TrkA) is overexpressed in oesophageal squamous cell carcinoma. Pathology, 2021, 53(4), 470-477.
[http://dx.doi.org/10.1016/j.pathol.2020.08.009] [PMID: 33143904]
[59]
Faulkner, S.; Jobling, P.; Rowe, C.W.; Rodrigues Oliveira, S.M.; Roselli, S.; Thorne, R.F.; Oldmeadow, C.; Attia, J.; Jiang, C.C.; Zhang, X.D.; Walker, M.M.; Hondermarck, H. Neurotrophin Receptors TrkA, p75NTR, and sortilin are increased and targetable in thyroid cancer. Am. J. Pathol., 2018, 188(1), 229-241.
[http://dx.doi.org/10.1016/j.ajpath.2017.09.008] [PMID: 29037860]
[60]
Xu, J.; Wang, R.; Wang, T.; Wang, T.; Gu, D.; He, Y.; Shu, Y.; Chen, R.; Liu, L. Targeted DNA profiling and the prevalence of NTRK aberrations in Chinese patients with head and neck cancer. Oral Oncol., 2021, 119, 105369.
[http://dx.doi.org/10.1016/j.oraloncology.2021.105369] [PMID: 34098386]
[61]
Yao, J.; Wang, A.; Wang, X.; Zhang, L.; Zhu, Y.; Ou, Y.; Wang, Z.; Yang, Y. Complete response to crizotinib in a metastatic adenocarcinoma of unknown primary harboring MET amplification and NTRK1 co-occurring mutation. OncoTargets Ther., 2019, 12, 4261-4267.
[http://dx.doi.org/10.2147/OTT.S202739] [PMID: 31213843]
[62]
Yang, K.; Xu, Y.C.; Hu, H.Y.; Li, Y.Z.; Li, Q.; Luan, Y.Y.; Liu, Y.; Sun, Y.Q.; Feng, Z.K.; Yan, Y.S.; Yin, C.H. Investigation of a novel NTRK1 variation causing congenital insensitivity to pain with anhidrosis. Front. Genet., 2021, 12, 763467.
[http://dx.doi.org/10.3389/fgene.2021.763467] [PMID: 34938316]
[63]
Shaikh, S.S.; Chen, Y.C.; Halsall, S.A.; Nahorski, M.S.; Omoto, K.; Young, G.T.; Phelan, A.; Woods, C.G. A comprehensive functional analysis of NTRK1 missense mutations causing hereditary sensory and autonomic neuropathy type IV (HSAN IV). Hum. Mutat., 2017, 38(1), 55-63.
[http://dx.doi.org/10.1002/humu.23123] [PMID: 27676246]
[64]
Tacconelli, A.; Farina, A.R.; Cappabianca, L.; Gulino, A.; Mackay, A.R. Alternative TrkAIII splicing: A potential regulated tumor-promoting switch and therapeutic target in neuroblastoma. Future Oncol., 2005, 1(5), 689-698.
[http://dx.doi.org/10.2217/14796694.1.5.689] [PMID: 16556046]
[65]
Reuther, G.W.; Lambert, Q.T.; Caligiuri, M.A.; Der, C.J. Identification and characterization of an activating TrkA deletion mutation in acute myeloid leukemia. Mol. Cell. Biol., 2000, 20(23), 8655-8666.
[http://dx.doi.org/10.1128/MCB.20.23.8655-8666.2000] [PMID: 11073967]
[66]
Gao, J.; Aksoy, B.A.; Dogrusoz, U.; Dresdner, G.; Gross, B.; Sumer, S.O.; Sun, Y.; Jacobsen, A.; Sinha, R.; Larsson, E.; Cerami, E.; Sander, C.; Schultz, N. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal., 2013, 6(269), pl1.
[http://dx.doi.org/10.1126/scisignal.2004088] [PMID: 23550210]
[67]
Lee, S.J.; Kim, N.K.D.; Lee, S.H.; Kim, S.T.; Park, S.H.; Park, J.O.; Park, Y.S.; Lim, H.Y.; Kang, W.K.; Park, W.Y.; Bang, H.J.; Kim, K-M.; Park, K.; Lee, J. NTRK gene amplification in patients with metastatic cancer. Precis. Futur. Med., 2017, 1(3), 129-137.
[http://dx.doi.org/10.23838/pfm.2017.00142]
[68]
Coleman, R.E. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin. Cancer Res., 2006, 12(20), 6243s-6249s.
[http://dx.doi.org/10.1158/1078-0432.CCR-06-0931] [PMID: 17062708]
[69]
Fang, X.; Djouhri, L.; McMullan, S.; Berry, C.; Okuse, K.; Waxman, S.G.; Lawson, S.N. trkA is expressed in nociceptive neurons and influences electrophysiological properties via Nav1.8 expression in rapidly conducting nociceptors. J. Neurosci., 2005, 25(19), 4868-4878.
[http://dx.doi.org/10.1523/JNEUROSCI.0249-05.2005] [PMID: 15888662]
[70]
Ramsey, I.S.; Delling, M.; Clapham, D.E. An introduction to TRP channels. Annu. Rev. Physiol., 2006, 68(1), 619-647.
[http://dx.doi.org/10.1146/annurev.physiol.68.040204.100431] [PMID: 16460286]
[71]
Franklin, S.L.; Davies, A.M.; Wyatt, S. Macrophage stimulating protein is a neurotrophic factor for a sub-population of adult nociceptive sensory neurons. Mol. Cell. Neurosci., 2009, 41(2), 175-185.
[http://dx.doi.org/10.1016/j.mcn.2009.02.009] [PMID: 19285136]
[72]
McKelvey, L.; Shorten, G.D.; O’Keeffe, G.W. Nerve growth factor-mediated regulation of pain signalling and proposed new intervention strategies in clinical pain management. J. Neurochem., 2013, 124(3), 276-289.
[http://dx.doi.org/10.1111/jnc.12093] [PMID: 23157347]
[73]
Moraes, B.C.; Ribeiro-Filho, H.V.; Roldão, A.P.; Toniolo, E.F.; Carretero, G.P.B.; Sgro, G.G.; Batista, F.A.H.; Berardi, D.E.; Oliveira, V.R.S.; Tomasin, R.; Vieceli, F.M.; Pramio, D.T.; Cardoso, A.B.; Figueira, A.C.M.; Farah, S.C.; Devi, L.A.; Dale, C.S.; de Oliveira, P.S.L.; Schechtman, D. Structural analysis of TrkA mutations in patients with congenital insensitivity to pain reveals PLCγ as an analgesic drug target. Sci. Signal., 2022, 15(731), eabm6046.
[http://dx.doi.org/10.1126/scisignal.abm6046] [PMID: 35471943]
[74]
Cancer genome atlas research network. Integrated genomic characterization of papillary thyroid carcinoma. Cell, 2014, 159(3), 676-690.
[http://dx.doi.org/10.1016/j.cell.2014.09.050] [PMID: 25417114]
[75]
Chu, Y.H.; Wirth, L.J.; Farahani, A.A.; Nosé, V.; Faquin, W.C.; Dias-Santagata, D.; Sadow, P.M. Clinicopathologic features of kinase fusion-related thyroid carcinomas: An integrative analysis with molecular characterization. Mod. Pathol., 2020, 33(12), 2458-2472.
[http://dx.doi.org/10.1038/s41379-020-0638-5] [PMID: 32737449]
[76]
Greco, A.; Miranda, C.; Pagliardini, S.; Fusetti, L.; Bongarzone, I.; Pierotti, M.A. Chromosome I rearrangements involving the genes TPR and NTRK1 produce structurally different thyroid-specific TRK oncogenes. Genes Chromosomes Cancer, 1997, 19(2), 112-123.
[http://dx.doi.org/10.1002/(SICI)1098-2264(199706)19:2<112:AID-GCC7>3.0.CO;2-1] [PMID: 9172002]
[77]
Pfeifer, A. Rusinek, D.; Żebracka-Gala, J.; Czarniecka, A.; Chmielik, E.; Zembala-Nożyńska, E.; Wojtaś, B.; Gielniewski, B.; Szpak-Ulczok, S.; Oczko-Wojciechowska, M.; Krajewska, J.; Polańska, J.; Jarząb, B. Novel TG‐FGFR1 and TRIM33‐NTRK1 transcript fusions in papillary thyroid carcinoma. Genes Chromosomes Cancer, 2019, 58(8), 558-566.
[http://dx.doi.org/10.1002/gcc.22737] [PMID: 30664823]
[78]
Shimura, K.; Shibata, H.; Mizuno, Y.; Amano, N.; Hoshino, K.; Kuroda, T.; Kameyama, K.; Matsuse, M.; Mitsutake, N.; Sugino, K.; Yoshimura Noh, J.; Hasegawa, T.; Ishii, T. Rapid growth and early metastasis of papillary thyroid carcinoma in an adolescent girl with graves’ disease. Horm. Res. Paediatr., 2019, 91(3), 210-215.
[http://dx.doi.org/10.1159/000491102] [PMID: 30092570]
[79]
Zheng, Z.; Liebers, M.; Zhelyazkova, B.; Cao, Y.; Panditi, D.; Lynch, K.D.; Chen, J.; Robinson, H.E.; Shim, H.S.; Chmielecki, J.; Pao, W.; Engelman, J.A.; Iafrate, A.J.; Le, L.P. Anchored multiplex PCR for targeted next-generation sequencing. Nat. Med., 2014, 20(12), 1479-1484.
[http://dx.doi.org/10.1038/nm.3729] [PMID: 25384085]
[80]
Park, J.C.; Ashok, A.; Liu, C.; Kang, H. Real-world experience of NTRK fusion–positive thyroid cancer. JCO Precis. Oncol., 2022, 6(6), e2100442.
[http://dx.doi.org/10.1200/PO.21.00442] [PMID: 35171659]
[81]
Lu, R.; Qi, C.; Xiao, M.; Cai, S.; Zheng, M. STRN3-NTRK1: A novel NTRK1 oncogenic fusion in a patient with lung adenocarcinoma. J. Thorac. Oncol., 2020, 15(2), e23-e24.
[http://dx.doi.org/10.1016/j.jtho.2019.08.2508] [PMID: 32127185]
[82]
Yang, S.; Li, L.; Chen, D.; Xiao, M.; Xian, L. EPS15–NTRK1: A novel NTRK1 oncogenic fusion in patient with lung adenocarcinoma. J. Cancer Res. Clin. Oncol., 2020, 146(12), 3389-3392.
[http://dx.doi.org/10.1007/s00432-020-03416-2] [PMID: 33037466]
[83]
Drilon, A.; Siena, S.; Ou, S.H.I.; Patel, M.; Ahn, M.J.; Lee, J.; Bauer, T.M.; Farago, A.F.; Wheler, J.J.; Liu, S.V.; Doebele, R.; Giannetta, L.; Cerea, G.; Marrapese, G.; Schirru, M.; Amatu, A.; Bencardino, K.; Palmeri, L.; Sartore-Bianchi, A.; Vanzulli, A.; Cresta, S.; Damian, S.; Duca, M.; Ardini, E.; Li, G.; Christiansen, J.; Kowalski, K.; Johnson, A.D.; Patel, R.; Luo, D.; Chow-Maneval, E.; Hornby, Z.; Multani, P.S.; Shaw, A.T.; De Braud, F.G. Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: Combined results from two phase I trials (ALKA-372-001 and STARTRK-1). Cancer Discov., 2017, 7(4), 400-409.
[http://dx.doi.org/10.1158/2159-8290.CD-16-1237] [PMID: 28183697]
[84]
Song, Z.; Xu, C.; Pu, X.; Zhu, Y.; Wang, W.; Li, X.; Gao, Y.; Zhu, W.; He, Y.; Wu, L.; Mao, L.; Chen, L.; Chen, M. High‐throughput sequencing detection and ensartinib treatment of lung cancer harboring NTRK1 fusion. Cancer Commun., 2021, 41(2), 192-196.
[http://dx.doi.org/10.1002/cac2.12133] [PMID: 33452864]
[85]
Xia, H.; Xue, X.; Ding, H.; Ou, Q.; Wu, X.; Nagasaka, M.; Shao, Y.W.; Hu, X.; Ou, S.H.I. Evidence of NTRK1 fusion as resistance mechanism to EGFR TKI in EGFR+ NSCLC: Results from a large-scale survey of NTRK1 fusions in chinese patients with lung cancer. Clin. Lung Cancer, 2020, 21(3), 247-254.
[http://dx.doi.org/10.1016/j.cllc.2019.09.004] [PMID: 31761448]
[86]
Zehir, A.; Benayed, R.; Shah, R.H.; Syed, A.; Middha, S.; Kim, H.R.; Srinivasan, P.; Gao, J.; Chakravarty, D.; Devlin, S.M.; Hellmann, M.D.; Barron, D.A.; Schram, A.M.; Hameed, M.; Dogan, S.; Ross, D.S.; Hechtman, J.F.; DeLair, D.F.; Yao, J.; Mandelker, D.L.; Cheng, D.T.; Chandramohan, R.; Mohanty, A.S.; Ptashkin, R.N.; Jayakumaran, G.; Prasad, M.; Syed, M.H.; Rema, A.B.; Liu, Z.Y.; Nafa, K.; Borsu, L.; Sadowska, J.; Casanova, J.; Bacares, R.; Kiecka, I.J.; Razumova, A.; Son, J.B.; Stewart, L.; Baldi, T.; Mullaney, K.A.; Al-Ahmadie, H.; Vakiani, E.; Abeshouse, A.A.; Penson, A.V.; Jonsson, P.; Camacho, N.; Chang, M.T.; Won, H.H.; Gross, B.E.; Kundra, R.; Heins, Z.J.; Chen, H.W.; Phillips, S.; Zhang, H.; Wang, J.; Ochoa, A.; Wills, J.; Eubank, M.; Thomas, S.B.; Gardos, S.M.; Reales, D.N.; Galle, J.; Durany, R.; Cambria, R.; Abida, W.; Cercek, A.; Feldman, D.R.; Gounder, M.M.; Hakimi, A.A.; Harding, J.J.; Iyer, G.; Janjigian, Y.Y.; Jordan, E.J.; Kelly, C.M.; Lowery, M.A.; Morris, L.G.T.; Omuro, A.M.; Raj, N.; Razavi, P.; Shoushtari, A.N.; Shukla, N.; Soumerai, T.E.; Varghese, A.M.; Yaeger, R.; Coleman, J.; Bochner, B.; Riely, G.J.; Saltz, L.B.; Scher, H.I.; Sabbatini, P.J.; Robson, M.E.; Klimstra, D.S.; Taylor, B.S.; Baselga, J.; Schultz, N.; Hyman, D.M.; Arcila, M.E.; Solit, D.B.; Ladanyi, M.; Berger, M.F. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat. Med., 2017, 23(6), 703-713.
[http://dx.doi.org/10.1038/nm.4333] [PMID: 28481359]
[87]
Cho, S.H.; Yoon, S.; Lee, D.H.; Kim, S.W.; Kim, K. Recurrence-associated gene signature in patients with stage I non-small-cell lung cancer. Sci. Rep., 2021, 11(1), 19596.
[http://dx.doi.org/10.1038/s41598-021-99197-w] [PMID: 34599262]
[88]
Ge, J.; Yao, B.; Huang, J.; Wu, X.; Bao, H.; Ou, Q.; Shao, Y.W.; Chen, J. Molecular genetic characterization reveals linear tumor evolution in a pulmonary sarcomatoid carcinomas patient with a novel PHF20-NTRK1 fusion: A case report. BMC Cancer, 2019, 19(1), 592.
[http://dx.doi.org/10.1186/s12885-019-5780-4] [PMID: 31208361]
[89]
Doebele, R.C.; Davis, L.E.; Vaishnavi, A.; Le, A.T.; Estrada-Bernal, A.; Keysar, S.; Jimeno, A.; Varella-Garcia, M.; Aisner, D.L.; Li, Y.; Stephens, P.J.; Morosini, D.; Tuch, B.B.; Fernandes, M.; Nanda, N.; Low, J.A. An oncogenic NTRK fusion in a patient with soft-tissue sarcoma with response to the tropomyosin-related kinase inhibitor LOXO-101. Cancer Discov., 2015, 5(10), 1049-1057.
[http://dx.doi.org/10.1158/2159-8290.CD-15-0443] [PMID: 26216294]
[90]
Recine, F.; De Vita, A.; Fausti, V.; Pieri, F.; Bongiovanni, A.; Franchini, E.; Casadei, R.; Falasconi, M.C.; Oboldi, D.; Matteucci, F.; Pallotti, M.C.; Mercatali, L.; Riva, N.; Gurrieri, L.; Vanni, S.; Liverani, C.; Miserocchi, G.; Spadazzi, C.; Cocchi, C.; Ibrahim, T. Case report: Adult NTRK-rearranged spindle cell neoplasm: Early tumor shrinkage in a case with bone and visceral metastases treated with targeted therapy. Front. Oncol., 2022, 11, 740676.
[http://dx.doi.org/10.3389/fonc.2021.740676] [PMID: 35070960]
[91]
Chiang, S.; Cotzia, P.; Hyman, D.M.; Drilon, A.; Tap, W.D.; Zhang, L.; Hechtman, J.F.; Frosina, D.; Jungbluth, A.A.; Murali, R.; Park, K.J.; Soslow, R.A.; Oliva, E.; Iafrate, A.J.; Benayed, R.; Ladanyi, M.; Antonescu, C.R. NTRK fusions define a novel uterine sarcoma subtype with features of fibrosarcoma. Am. J. Surg. Pathol., 2018, 42(6), 791-798.
[http://dx.doi.org/10.1097/PAS.0000000000001055] [PMID: 29553955]
[92]
Agaram, N.P.; Zhang, L.; Sung, Y.S.; Chen, C.L.; Chung, C.T.; Antonescu, C.R.; Fletcher, C.D.M. Recurrent NTRK1 gene fusions define a novel subset of locally aggressive lipofibromatosis-like neural tumors. Am. J. Surg. Pathol., 2016, 40(10), 1407-1416.
[http://dx.doi.org/10.1097/PAS.0000000000000675] [PMID: 27259011]
[93]
Knezevich, S.R.; McFadden, D.E.; Tao, W.; Lim, J.F.; Sorensen, P.H.B. A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma. Nat. Genet., 1998, 18(2), 184-187.
[http://dx.doi.org/10.1038/ng0298-184] [PMID: 9462753]
[94]
Martin-Zanca, D.; Hughes, S.H.; Barbacid, M. A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences. Nature, 1986, 319(6056), 743-748.
[http://dx.doi.org/10.1038/319743a0] [PMID: 2869410]
[95]
Créancier, L.; Vandenberghe, I.; Gomes, B.; Dejean, C.; Blanchet, J.C.; Meilleroux, J.; Guimbaud, R.; Selves, J.; Kruczynski, A. Chromosomal rearrangements involving the NTRK1 gene in colorectal carcinoma. Cancer Lett., 2015, 365(1), 107-111.
[http://dx.doi.org/10.1016/j.canlet.2015.05.013] [PMID: 26001971]
[96]
Pekova, B.; Sykorova, V.; Mastnikova, K.; Vaclavikova, E.; Moravcova, J.; Vlcek, P.; Lastuvka, P.; Taudy, M.; Katra, R.; Bavor, P.; Kodetova, D.; Chovanec, M.; Drozenova, J.; Astl, J.; Hrabal, P.; Vcelak, J.; Bendlova, B. NTRK fusion genes in thyroid carcinomas: Clinicopathological characteristics and their impacts on prognosis. Cancers, 2021, 13(8), 1932.
[http://dx.doi.org/10.3390/cancers13081932] [PMID: 33923728]
[97]
Prasad, M.L.; Vyas, M.; Horne, M.J.; Virk, R.K.; Morotti, R.; Liu, Z.; Tallini, G.; Nikiforova, M.N.; Christison-Lagay, E.R.; Udelsman, R.; Dinauer, C.A.; Nikiforov, Y.E. NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States. Cancer, 2016, 122(7), 1097-1107.
[http://dx.doi.org/10.1002/cncr.29887] [PMID: 26784937]
[98]
Frattini, V.; Trifonov, V.; Chan, J.M.; Castano, A.; Lia, M.; Abate, F.; Keir, S.T.; Ji, A.X.; Zoppoli, P.; Niola, F.; Danussi, C.; Dolgalev, I.; Porrati, P.; Pellegatta, S.; Heguy, A.; Gupta, G.; Pisapia, D.J.; Canoll, P.; Bruce, J.N.; McLendon, R.E.; Yan, H.; Aldape, K.; Finocchiaro, G.; Mikkelsen, T.; Privé, G.G.; Bigner, D.D.; Lasorella, A.; Rabadan, R.; Iavarone, A. The integrated landscape of driver genomic alterations in glioblastoma. Nat. Genet., 2013, 45(10), 1141-1149.
[http://dx.doi.org/10.1038/ng.2734] [PMID: 23917401]
[99]
Kim, J.; Lee, Y.; Cho, H.J.; Lee, Y.E.; An, J.; Cho, G.H.; Ko, Y.H.; Joo, K.M.; Nam, D.H. NTRK1 fusion in glioblastoma multiforme. PLoS One, 2014, 9(3), e91940.
[http://dx.doi.org/10.1371/journal.pone.0091940] [PMID: 24647444]
[100]
Singh, D.; Chan, J.M.; Zoppoli, P.; Niola, F.; Sullivan, R.; Castano, A.; Liu, E.M.; Reichel, J.; Porrati, P.; Pellegatta, S.; Qiu, K.; Gao, Z.; Ceccarelli, M.; Riccardi, R.; Brat, D.J.; Guha, A.; Aldape, K.; Golfinos, J.G.; Zagzag, D.; Mikkelsen, T.; Finocchiaro, G.; Lasorella, A.; Rabadan, R.; Iavarone, A. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science, 2012, 337(6099), 1231-1235.
[http://dx.doi.org/10.1126/science.1220834] [PMID: 22837387]
[101]
Alvarez-Breckenridge, C.; Miller, J.J.; Nayyar, N.; Gill, C.M.; Kaneb, A.; D’Andrea, M.; Le, L.P.; Lee, J.; Cheng, J.; Zheng, Z.; Butler, W.E.; Multani, P.; Chow Maneval, E.; Ha Paek, S.; Toyota, B.D.; Dias-Santagata, D.; Santagata, S.; Romero, J.; Shaw, A.T.; Farago, A.F.; Yip, S.; Cahill, D.P.; Batchelor, T.T.; Iafrate, A.J.; Brastianos, P.K. Clinical and radiographic response following targeting of BCAN-NTRK1 fusion in glioneuronal tumor. NPJ Precis. Oncol., 2017, 1(1), 5.
[http://dx.doi.org/10.1038/s41698-017-0009-y] [PMID: 29872694]
[102]
Shinozaki-Ushiku, A.; Ishikawa, S.; Komura, D.; Seto, Y.; Aburatani, H.; Ushiku, T. The first case of gastric carcinoma with NTRK rearrangement: Identification of a novel ATP1B–NTRK1 fusion. Gastric Cancer, 2020, 23(5), 944-947.
[http://dx.doi.org/10.1007/s10120-020-01061-9] [PMID: 32189226]
[103]
Kohsaka, S.; Saito, T.; Akaike, K.; Suehara, Y.; Hayashi, T.; Takagi, T.; Kaneko, K.; Ueno, T.; Kojima, S.; Kohashi, K.; Mano, H.; Oda, Y.; Yao, T. Pediatric soft tissue tumor of the upper arm with LMNA-NTRK1 fusion. Hum. Pathol., 2018, 72, 167-173.
[http://dx.doi.org/10.1016/j.humpath.2017.08.017] [PMID: 28851664]
[104]
Yamashiro, Y.; Kurihara, T.; Hayashi, T.; Suehara, Y.; Yao, T.; Kato, S.; Saito, T. NTRK fusion in Japanese colorectal adenocarcinomas. Sci. Rep., 2021, 11(1), 5635.
[http://dx.doi.org/10.1038/s41598-021-85075-y] [PMID: 33707574]
[105]
Russo, M.; Misale, S.; Wei, G.; Siravegna, G.; Crisafulli, G.; Lazzari, L.; Corti, G.; Rospo, G.; Novara, L.; Mussolin, B.; Bartolini, A.; Cam, N.; Patel, R.; Yan, S.; Shoemaker, R.; Wild, R.; Di Nicolantonio, F.; Bianchi, A.S.; Li, G.; Siena, S.; Bardelli, A. Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer. Cancer Discov., 2016, 6(1), 36-44.
[http://dx.doi.org/10.1158/2159-8290.CD-15-0940] [PMID: 26546295]
[106]
Pietrantonio, F.; Di Nicolantonio, F.; Schrock, A.B.; Lee, J.; Tejpar, S.; Sartore-Bianchi, A.; Hechtman, J.F.; Christiansen, J.; Novara, L.; Tebbutt, N.; Fucà, G.; Antoniotti, C.; Kim, S.T.; Murphy, D.; Berenato, R.; Morano, F.; Sun, J.; Min, B.; Stephens, P.J.; Chen, M.; Lazzari, L.; Miller, V.A.; Shoemaker, R.; Amatu, A.; Milione, M.; Ross, J.S.; Siena, S.; Bardelli, A.; Ali, S.M.; Falcone, A.; de Braud, F.; Cremolini, C. ALK, ROS1, and NTRK rearrangements in metastatic colorectal cancer. J. Natl. Cancer Inst., 2017, 109(12)
[http://dx.doi.org/10.1093/jnci/djx089] [PMID: 29370427]
[107]
Hechtman, J.F.; Benayed, R.; Hyman, D.M.; Drilon, A.; Zehir, A.; Frosina, D.; Arcila, M.E.; Dogan, S.; Klimstra, D.S.; Ladanyi, M.; Jungbluth, A.A. Pan-Trk immunohistochemistry is an efficient and reliable screen for the detection of NTRK fusions. Am. J. Surg. Pathol., 2017, 41(11), 1547-1551.
[http://dx.doi.org/10.1097/PAS.0000000000000911] [PMID: 28719467]
[108]
Qaddoumi, I.; Orisme, W.; Wen, J.; Santiago, T.; Gupta, K.; Dalton, J.D.; Tang, B.; Haupfear, K.; Punchihewa, C.; Easton, J.; Mulder, H.; Boggs, K.; Shao, Y.; Rusch, M.; Becksfort, J.; Gupta, P.; Wang, S.; Lee, R.P.; Brat, D.; Peter Collins, V.; Dahiya, S.; George, D.; Konomos, W.; Kurian, K.M.; McFadden, K.; Serafini, L.N.; Nickols, H.; Perry, A.; Shurtleff, S.; Gajjar, A.; Boop, F.A.; Klimo, P.D., Jr; Mardis, E.R.; Wilson, R.K.; Baker, S.J.; Zhang, J.; Wu, G.; Downing, J.R.; Tatevossian, R.G.; Ellison, D.W. Genetic alterations in uncommon low-grade neuroepithelial tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology. Acta Neuropathol., 2016, 131(6), 833-845.
[http://dx.doi.org/10.1007/s00401-016-1539-z] [PMID: 26810070]
[109]
Stransky, N.; Cerami, E.; Schalm, S.; Kim, J.L.; Lengauer, C. The landscape of kinase fusions in cancer. Nat. Commun., 2014, 5(1), 4846.
[http://dx.doi.org/10.1038/ncomms5846] [PMID: 25204415]
[110]
López, G.Y.; Perry, A.; Harding, B.; Li, M.; Santi, M. CDKN2A/B loss is associated with anaplastic transformation in a case of NTRK2 fusion-positive pilocytic astrocytoma. Neuropathol. Appl. Neurobiol., 2019, 45(2), 174-178.
[http://dx.doi.org/10.1111/nan.12503] [PMID: 29804288]
[111]
Prabhakaran, N.; Guzman, M.A.; Navalkele, P.; Chow-Maneval, E.; Batanian, J.R. Novel TLE4-NTRK2 fusion in a ganglioglioma identified by array-CGH and confirmed by NGS: Potential for a gene targeted therapy. Neuropathology, 2018, 38(4), 380-386.
[http://dx.doi.org/10.1111/neup.12458] [PMID: 29502353]
[112]
Jones, D.T.W. Hutter, B.; Jäger, N.; Korshunov, A.; Kool, M.; Warnatz, H.J.; Zichner, T.; Lambert, S.R.; Ryzhova, M.; Quang, D.A.K.; Fontebasso, A.M.; Stütz, A.M.; Hutter, S.; Zuckermann, M.; Sturm, D.; Gronych, J.; Lasitschka, B.; Schmidt, S.; Şeker-Cin, H.; Witt, H.; Sultan, M.; Ralser, M.; Northcott, P.A.; Hovestadt, V.; Bender, S.; Pfaff, E.; Stark, S.; Faury, D.; Schwartzentruber, J.; Majewski, J.; Weber, U.D.; Zapatka, M.; Raeder, B.; Schlesner, M.; Worth, C.L.; Bartholomae, C.C.; von Kalle, C.; Imbusch, C.D.; Radomski, S.; Lawerenz, C.; van Sluis, P.; Koster, J.; Volckmann, R.; Versteeg, R.; Lehrach, H.; Monoranu, C.; Winkler, B.; Unterberg, A.; Herold-Mende, C.; Milde, T.; Kulozik, A.E.; Ebinger, M.; Schuhmann, M.U.; Cho, Y.J.; Pomeroy, S.L.; von Deimling, A.; Witt, O.; Taylor, M.D.; Wolf, S.; Karajannis, M.A.; Eberhart, C.G.; Scheurlen, W.; Hasselblatt, M.; Ligon, K.L.; Kieran, M.W.; Korbel, J.O.; Yaspo, M.L.; Brors, B.; Felsberg, J.; Reifenberger, G.; Collins, V.P.; Jabado, N.; Eils, R.; Lichter, P.; Pfister, S.M. Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat. Genet., 2013, 45(8), 927-932.
[http://dx.doi.org/10.1038/ng.2682] [PMID: 23817572]
[113]
Michal, M.; Hájková, V.; Skálová, A.; Michal, M. STRN-NTRK3-rearranged mesenchymal tumor of the uterus. Am. J. Surg. Pathol., 2019, 43(8), 1152-1154.
[http://dx.doi.org/10.1097/PAS.0000000000001292] [PMID: 31107720]
[114]
Yeh, I.; Tee, M.K.; Botton, T.; Shain, A.H.; Sparatta, A.J.; Gagnon, A.; Vemula, S.S.; Garrido, M.C.; Nakamaru, K.; Isoyama, T.; McCalmont, T.H.; LeBoit, P.E.; Bastian, B.C. NTRK3 kinase fusions in Spitz tumours. J. Pathol., 2016, 240(3), 282-290.
[http://dx.doi.org/10.1002/path.4775] [PMID: 27477320]
[115]
Wu, G.; Diaz, A.K.; Paugh, B.S.; Rankin, S.L.; Ju, B.; Li, Y.; Zhu, X.; Qu, C.; Chen, X.; Zhang, J.; Easton, J.; Edmonson, M.; Ma, X.; Lu, C.; Nagahawatte, P.; Hedlund, E.; Rusch, M.; Pounds, S.; Lin, T.; Onar-Thomas, A.; Huether, R.; Kriwacki, R.; Parker, M.; Gupta, P.; Becksfort, J.; Wei, L.; Mulder, H.L.; Boggs, K.; Vadodaria, B.; Yergeau, D.; Russell, J.C.; Ochoa, K.; Fulton, R.S.; Fulton, L.L.; Jones, C.; Boop, F.A.; Broniscer, A.; Wetmore, C.; Gajjar, A.; Ding, L.; Mardis, E.R.; Wilson, R.K.; Taylor, M.R.; Downing, J.R.; Ellison, D.W.; Zhang, J.; Baker, S.J. The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nat. Genet., 2014, 46(5), 444-450.
[http://dx.doi.org/10.1038/ng.2938] [PMID: 24705251]
[116]
Seethala, R.R.; Chiosea, S.I.; Liu, C.Z.; Nikiforova, M.; Nikiforov, Y.E. Clinical and morphologic features of ETV6-NTRK3 translocated papillary thyroid carcinoma in an adult population without radiation exposure. Am. J. Surg. Pathol., 2017, 41(4), 446-457.
[http://dx.doi.org/10.1097/PAS.0000000000000814] [PMID: 28125451]
[117]
Iyama, K.; Matsuse, M.; Mitsutake, N.; Rogounovitch, T.; Saenko, V.; Suzuki, K. Identification of three novel fusion oncogenes, Sqstm1/Ntrk3, Afap1l2/Ret, and Ppfibp2/Ret, in thyroid cancers of young patients in Fukushima. Thyroid, 2017, 27(6), 811-818.
[http://dx.doi.org/10.1089/thy.2016.0673]
[118]
Tallegas, M.; Fraitag, S.; Binet, A.; Orbach, D.; Jourdain, A. Reynaud, S Novel Khdrbs1-Ntrk3 rearrangement in a congenital pediatric Cd34-positive skin tumor: A case report. Int. J. Pathol., 2019, 474(1), 111-115.
[http://dx.doi.org/10.1007/s00428-018-2415-0]
[119]
Farago, A.F.; Taylor, M.S.; Doebele, R.C.; Zhu, V.W.; Kummar, S.; Spira, A.I.; Boyle, T.A.; Haura, E.B.; Arcila, M.E.; Benayed, R.; Aisner, D.L.; Horick, N.K.; Lennerz, J.K.; Le, L.P.; Iafrate, A.J.; Ou, S.H.I.; Shaw, A.T.; Mino-Kenudson, M.; Drilon, A. Clinicopathologic features of non–small-cell lung cancer harboring an NTRK gene fusion. JCO Precis. Oncol., 2018, 2018(2), 1-12.
[http://dx.doi.org/10.1200/PO.18.00037] [PMID: 30215037]
[120]
Drilon, A.; Laetsch, T.W.; Kummar, S.; DuBois, S.G.; Lassen, U.N.; Demetri, G.D.; Nathenson, M.; Doebele, R.C.; Farago, A.F.; Pappo, A.S.; Turpin, B.; Dowlati, A.; Brose, M.S.; Mascarenhas, L.; Federman, N.; Berlin, J.; El-Deiry, W.S.; Baik, C.; Deeken, J.; Boni, V.; Nagasubramanian, R.; Taylor, M.; Rudzinski, E.R.; Meric-Bernstam, F.; Sohal, D.P.S.; Ma, P.C.; Raez, L.E.; Hechtman, J.F.; Benayed, R.; Ladanyi, M.; Tuch, B.B.; Ebata, K.; Cruickshank, S.; Ku, N.C.; Cox, M.C.; Hawkins, D.S.; Hong, D.S.; Hyman, D.M. Efficacy of larotrectinib in TRK fusion–positive cancers in adults and children. N. Engl. J. Med., 2018, 378(8), 731-739.
[http://dx.doi.org/10.1056/NEJMoa1714448] [PMID: 29466156]
[121]
Okamura, R.; Boichard, A.; Kato, S.; Sicklick, J.K.; Bazhenova, L.; Kurzrock, R. Analysis of NTRK alterations in pan-cancer adult and pediatric malignancies: Implications for NTRK-targeted therapeutics. JCO Precis. Oncol., 2018, 2018(2), 1-20.
[http://dx.doi.org/10.1200/PO.18.00183] [PMID: 30637364]
[122]
Brenca, M.; Rossi, S.; Polano, M.; Gasparotto, D.; Zanatta, L.; Racanelli, D.; Valori, L.; Lamon, S.; Dei Tos, A.P.; Maestro, R. Transcriptome sequencing identifies ETV6-NTRK3 as a gene fusion involved in GIST. J. Pathol., 2016, 238(4), 543-549.
[http://dx.doi.org/10.1002/path.4677] [PMID: 26606880]
[123]
Taylor, J.; Pavlick, D.; Yoshimi, A.; Marcelus, C.; Chung, S.S.; Hechtman, J.F.; Benayed, R.; Cocco, E.; Durham, B.H.; Bitner, L.; Inoue, D.; Chung, Y.R.; Mullaney, K.; Watts, J.M.; Diamond, E.L.; Albacker, L.A.; Mughal, T.I.; Ebata, K.; Tuch, B.B.; Ku, N.; Scaltriti, M.; Roshal, M.; Arcila, M.; Ali, S.; Hyman, D.M.; Park, J.H.; Abdel-Wahab, O. Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies. J. Clin. Invest., 2018, 128(9), 3819-3825.
[http://dx.doi.org/10.1172/JCI120787] [PMID: 29920189]
[124]
Laé, M.; Fréneaux, P.; Sastre-Garau, X.; Chouchane, O.; Sigal-Zafrani, B.; Vincent-Salomon, A. Secretory breast carcinomas with ETV6-NTRK3 fusion gene belong to the basal-like carcinoma spectrum. Mod. Pathol., 2009, 22(2), 291-298.
[http://dx.doi.org/10.1038/modpathol.2008.184] [PMID: 19011601]
[125]
Lezcano, C.; Shoushtari, A.N.; Ariyan, C.; Hollmann, T.J.; Busam, K.J. Primary and metastatic melanoma with NTRK fusions. Am. J. Surg. Pathol., 2018, 42(8), 1052-1058.
[http://dx.doi.org/10.1097/PAS.0000000000001070] [PMID: 29683819]
[126]
Bagal, S.K.; Andrews, M.; Bechle, B.M.; Bian, J.; Bilsland, J.; Blakemore, D.C.; Braganza, J.F.; Bungay, P.J.; Corbett, M.S.; Cronin, C.N.; Cui, J.J.; Dias, R.; Flanagan, N.J.; Greasley, S.E.; Grimley, R.; James, K.; Johnson, E.; Kitching, L.; Kraus, M.L.; McAlpine, I.; Nagata, A.; Ninkovic, S.; Omoto, K.; Scales, S.; Skerratt, S.E.; Sun, J.; Tran-Dubé, M.; Waldron, G.J.; Wang, F.; Warmus, J.S. Discovery of potent, selective, and peripherally restricted pan-Trk kinase inhibitors for the treatment of pain. J. Med. Chem., 2018, 61(15), 6779-6800.
[http://dx.doi.org/10.1021/acs.jmedchem.8b00633] [PMID: 29944371]
[127]
Larotrectinib, O K’d for Cancers with TRK Fusions. Cancer Discov., 2019, 9(1), 8-9.
[http://dx.doi.org/10.1158/2159-8290.CD-NB2018-163] [PMID: 30510115]
[128]
Scott, L.J. Larotrectinib: First global approval. Drugs, 2019, 79(2), 201-206.
[http://dx.doi.org/10.1007/s40265-018-1044-x] [PMID: 30635837]
[129]
Davies, K.D.; Mahale, S.; Astling, D.P.; Aisner, D.L.; Le, A.T.; Hinz, T.K.; Vaishnavi, A.; Bunn, P.A., Jr; Heasley, L.E.; Tan, A.C.; Camidge, D.R.; Varella-Garcia, M.; Doebele, R.C. Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer. PLoS One, 2013, 8(12), e82236.
[http://dx.doi.org/10.1371/journal.pone.0082236] [PMID: 24349229]
[130]
Taipale, M.; Krykbaeva, I.; Whitesell, L.; Santagata, S.; Zhang, J.; Liu, Q.; Gray, N.S.; Lindquist, S. Chaperones as thermodynamic sensors of drug-target interactions reveal kinase inhibitor specificities in living cells. Nat. Biotechnol., 2013, 31(7), 630-637.
[http://dx.doi.org/10.1038/nbt.2620] [PMID: 23811600]
[131]
Laetsch, T.W.; DuBois, S.G.; Mascarenhas, L.; Turpin, B.; Federman, N.; Albert, C.M.; Nagasubramanian, R.; Davis, J.L.; Rudzinski, E.; Feraco, A.M.; Tuch, B.B.; Ebata, K.T.; Reynolds, M.; Smith, S.; Cruickshank, S.; Cox, M.C.; Pappo, A.S.; Hawkins, D.S. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: Phase 1 results from a multicentre, open-label, phase 1/2 study. Lancet Oncol., 2018, 19(5), 705-714.
[http://dx.doi.org/10.1016/S1470-2045(18)30119-0] [PMID: 29606586]
[132]
DuBois, S.G.; Laetsch, T.W.; Federman, N.; Turpin, B.K.; Albert, C.M.; Nagasubramanian, R.; Anderson, M.E.; Davis, J.L.; Qamoos, H.E.; Reynolds, M.E.; Cruickshank, S.; Cox, M.C.; Hawkins, D.S.; Mascarenhas, L.; Pappo, A.S. The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas. Cancer, 2018, 124(21), 4241-4247.
[http://dx.doi.org/10.1002/cncr.31701] [PMID: 30204247]
[133]
Hong, D.S.; DuBois, S.G.; Kummar, S.; Farago, A.F.; Albert, C.M.; Rohrberg, K.S.; van Tilburg, C.M.; Nagasubramanian, R.; Berlin, J.D.; Federman, N.; Mascarenhas, L.; Geoerger, B.; Dowlati, A.; Pappo, A.S.; Bielack, S.; Doz, F.; McDermott, R.; Patel, J.D.; Schilder, R.J.; Tahara, M.; Pfister, S.M.; Witt, O.; Ladanyi, M.; Rudzinski, E.R.; Nanda, S.; Childs, B.H.; Laetsch, T.W.; Hyman, D.M.; Drilon, A. Larotrectinib in patients with TRK fusion-positive solid tumours: A pooled analysis of three phase 1/2 clinical trials. Lancet Oncol., 2020, 21(4), 531-540.
[http://dx.doi.org/10.1016/S1470-2045(19)30856-3] [PMID: 32105622]
[134]
Al-Salama, Z.T.; Keam, S.J. Entrectinib: First global approval. Drugs, 2019, 79(13), 1477-1483.
[http://dx.doi.org/10.1007/s40265-019-01177-y] [PMID: 31372957]
[135]
Drilon, A.; Siena, S.; Dziadziuszko, R.; Barlesi, F.; Krebs, M.G.; Shaw, A.T.; de Braud, F.; Rolfo, C.; Ahn, M.J.; Wolf, J.; Seto, T.; Cho, B.C.; Patel, M.R.; Chiu, C.H.; John, T.; Goto, K.; Karapetis, C.S.; Arkenau, H.T.; Kim, S.W.; Ohe, Y.; Li, Y.C.; Chae, Y.K.; Chung, C.H.; Otterson, G.A.; Murakami, H.; Lin, C.C.; Tan, D.S.W.; Prenen, H.; Riehl, T.; Chow-Maneval, E.; Simmons, B.; Cui, N.; Johnson, A.; Eng, S.; Wilson, T.R.; Doebele, R.C. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: Integrated analysis of three phase 1–2 trials. Lancet Oncol., 2020, 21(2), 261-270.
[http://dx.doi.org/10.1016/S1470-2045(19)30690-4] [PMID: 31838015]
[136]
Doebele, R.C.; Drilon, A.; Paz-Ares, L.; Siena, S.; Shaw, A.T.; Farago, A.F.; Blakely, C.M.; Seto, T.; Cho, B.C.; Tosi, D.; Besse, B.; Chawla, S.P.; Bazhenova, L.; Krauss, J.C.; Chae, Y.K.; Barve, M.; Garrido-Laguna, I.; Liu, S.V.; Conkling, P.; John, T.; Fakih, M.; Sigal, D.; Loong, H.H.; Buchschacher, G.L., Jr; Garrido, P.; Nieva, J.; Steuer, C.; Overbeck, T.R.; Bowles, D.W.; Fox, E.; Riehl, T.; Chow-Maneval, E.; Simmons, B.; Cui, N.; Johnson, A.; Eng, S.; Wilson, T.R.; Demetri, G.D. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: Integrated analysis of three phase 1–2 trials. Lancet Oncol., 2020, 21(2), 271-282.
[http://dx.doi.org/10.1016/S1470-2045(19)30691-6] [PMID: 31838007]
[137]
Shaw, A.T.; Riely, G.J.; Bang, Y.J.; Kim, D.W.; Camidge, D.R.; Solomon, B.J.; Varella-Garcia, M.; Iafrate, A.J.; Shapiro, G.I.; Usari, T.; Wang, S.C.; Wilner, K.D.; Clark, J.W.; Ou, S.H.I. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): Updated results, including overall survival, from PROFILE 1001. Ann. Oncol., 2019, 30(7), 1121-1126.
[http://dx.doi.org/10.1093/annonc/mdz131] [PMID: 30980071]
[138]
Wang, B.; Gao, Y.; Huang, Y.; Ou, Q.; Fang, T.; Tang, C.; Wu, X.; Shao, Y.W. Durable clinical response to crizotinib in IRF2BP2-NTRK1 non–small-cell lung cancer. Clin. Lung Cancer, 2019, 20(3), e233-e237.
[http://dx.doi.org/10.1016/j.cllc.2018.12.017] [PMID: 30691963]
[139]
Drilon, A.; Li, G.; Dogan, S.; Gounder, M.; Shen, R.; Arcila, M.; Wang, L.; Hyman, D.M.; Hechtman, J.; Wei, G.; Cam, N.R.; Christiansen, J.; Luo, D.; Maneval, E.C.; Bauer, T.; Patel, M.; Liu, S.V.; Ou, S.H.I.; Farago, A.; Shaw, A.; Shoemaker, R.F.; Lim, J.; Hornby, Z.; Multani, P.; Ladanyi, M.; Berger, M.; Katabi, N.; Ghossein, R.; Ho, A.L. What hides behind the MASC: Clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC). Ann. Oncol., 2016, 27(5), 920-926.
[http://dx.doi.org/10.1093/annonc/mdw042] [PMID: 26884591]
[140]
Duan, Y.; Wang, J.; Zhu, S.; Tu, Z.C.; Zhang, Z.; Chan, S.; Ding, K. Design, synthesis, and Structure–Activity Relationships (SAR) of 3-vinylindazole derivatives as new selective tropomyosin receptor kinases (Trk) inhibitors. Eur. J. Med. Chem., 2020, 203, 112552.
[http://dx.doi.org/10.1016/j.ejmech.2020.112552] [PMID: 32702585]
[141]
Drilon, A. Trk inhibitors in trk fusion-positive cancers. ESMO, 2019, 203, 112552.
[http://dx.doi.org/10.1093/annonc/mdz282]
[142]
Cocco, E.; Schram, A.M.; Kulick, A.; Misale, S.; Won, H.H.; Yaeger, R.; Razavi, P.; Ptashkin, R.; Hechtman, J.F.; Toska, E.; Cownie, J.; Somwar, R.; Shifman, S.; Mattar, M.; Selçuklu, S.D.; Samoila, A.; Guzman, S.; Tuch, B.B.; Ebata, K.; de Stanchina, E.; Nagy, R.J.; Lanman, R.B.; Houck-Loomis, B.; Patel, J.A.; Berger, M.F.; Ladanyi, M.; Hyman, D.M.; Drilon, A.; Scaltriti, M. Resistance to TRK inhibition mediated by convergent MAPK pathway activation. Nat. Med., 2019, 25(9), 1422-1427.
[http://dx.doi.org/10.1038/s41591-019-0542-z] [PMID: 31406350]
[143]
Wu, L.W.; Pavlock, T.; Patterson, A.; Post, A.; Ambrose, C.; Rajaram, V.; Pavlick, D.C.; Cooke, M.; Miller, V.A.; Albacker, L.A.; Ali, S.M.; Smith, S.; Cox, M.C.; Martin, A.; Megison, S.; Laetsch, T.W. Durable clinical response to larotrectinib in an adolescent patient with an undifferentiated sarcoma harboring an STRN-NTRK2 fusion. JCO Precis. Oncol., 2018, 2(2), 1-8.
[http://dx.doi.org/10.1200/PO.18.00101] [PMID: 32913990]
[144]
Ziegler, D.S.; Wong, M.; Mayoh, C.; Kumar, A.; Tsoli, M.; Mould, E.; Tyrrell, V.; Khuong-Quang, D.A.; Pinese, M.; Gayevskiy, V.; Cohn, R.J.; Lau, L.M.S.; Reynolds, M.; Cox, M.C.; Gifford, A.; Rodriguez, M.; Cowley, M.J.; Ekert, P.G.; Marshall, G.M.; Haber, M. Brief Report: Potent clinical and radiological response to larotrectinib in TRK fusion-driven high-grade glioma. Br. J. Cancer, 2018, 119(6), 693-696.
[http://dx.doi.org/10.1038/s41416-018-0251-2] [PMID: 30220707]
[145]
Laetsch, T.W.; Hong, D.S. Tropomyosin receptor kinase inhibitors for the treatment of TRK fusion cancer. Clin. Cancer Res., 2021, 27(18), 4974-4982.
[http://dx.doi.org/10.1158/1078-0432.CCR-21-0465] [PMID: 33893159]
[146]
Drilon, A.; Ou, S.H.I.; Cho, B.C.; Kim, D.W.; Lee, J.; Lin, J.J.; Zhu, V.W.; Ahn, M.J.; Camidge, D.R.; Nguyen, J.; Zhai, D.; Deng, W.; Huang, Z.; Rogers, E.; Liu, J.; Whitten, J.; Lim, J.K.; Stopatschinskaja, S.; Hyman, D.M.; Doebele, R.C.; Cui, J.J.; Shaw, A.T. Repotrectinib (TPX-0005) is a next-generation ROS1/TRK/ALK inhibitor that potently inhibits ROS1/TRK/ALK solvent- front mutations. Cancer Discov., 2018, 8(10), 1227-1236.
[http://dx.doi.org/10.1158/2159-8290.CD-18-0484] [PMID: 30093503]

Rights & Permissions Print Cite
Article Metrics
32
2
Wayfinder Image
© 2024 Bentham Science Publishers | Privacy Policy